Recursion Pharmaceuticals, Inc. RXRX Total debt
Total debt at other companies
Other financials
Where this comes from
Calculated from Recursion Pharmaceuticals, Inc.’s reported figures.
Plus components not separately reported this period.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s total debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s total debt?
- Recursion Pharmaceuticals, Inc. (RXRX) reported total debt of $88.58M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s total debt changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s total debt decreased by 24.6% year-over-year, from $117.51M to $88.58M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s total debt?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s total debt has grown at a 53.2% compound annual growth rate (CAGR), from $11.41M to $96.3M.
- What does total debt mean?
- Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.